Business Standard

Pharma SMEs will overcome short-term disruptions: CRISIL SME Tracker

Short-term disruptions include high input costs and various operational challenges.

medicine, drugs, pharma
Premium

Pharmaceuticals, being an essential commodity, is better-placed than other sectors to weather the storm.

Business Standard New Delhi
The Indian pharmaceuticals industry is very fragmented, with small and medium enterprises (SMEs) accounting for 35-40 per cent of production in value terms. The industry is currently facing uncertainty in the wake of the Covid-19 pandemic. However, going ahead, SMEs in this sector will overcome the short-term disruptions, as demand in both export and domestic markets remains robust.
 
Short-term disruptions include high input costs and various operational challenges. Although China has gradually resumed production of raw materials following disruptions in February and March this year, the cost of inputs remains high. While Indian companies have started receiving supplies, their average

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in